Show simple item record

dc.contributor.authorCabeza Montilla, Laura 
dc.contributor.authorOrtiz Quesada, Raúl 
dc.contributor.authorJiménez López, Julia
dc.contributor.authorPerazzoli, Gloria
dc.contributor.authorBaeyens Cabrera, José Manuel 
dc.contributor.authorMelguizo Alonso, Consolación 
dc.contributor.authorPrados Salazar, José Carlos
dc.identifier.citationCabeza, L... [et al.] (2022). Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer. BioImpacts, 2022, 12(x), x-x. doi: [10.34172/bi.2022.23433]es_ES
dc.descriptionFinancial support from the V Plan Propio (University of Seville). This work was also supported by Consejeria de Salud de la Junta de Andalucia (PI-0102-2017 and P18-HO-3882) and Instituto de Salud Carlos III (ISCIII) (Project PI19/01478) (FEDER).es_ES
dc.description.abstractIntroduction: Paclitaxel (PTX) is a cornerstone in the treatment of breast cancer, the most common type of cancer in women. However, this drug has serious limitations, including lack of tissue-specificity, poor water solubility, and the development of drug resistance. The transport of PTX in a polymeric nanoformulation could overcome these limitations. Methods: In this study, PLGA-PTX nanoparticles (NPs) were assayed in breast cancer cell lines, breast cancer stem cells (CSCs) and multicellular tumor spheroids (MTSs) analyzing cell cycle, cell uptake (Nile Red-NR-) and α-tubulin expression. In addition, PLGA-PTX NPs were tested in vivo using C57BL/6 mice, including a biodistribution assay. Results: PTX-PLGA NPs induced a significant decrease in the PTX IC50 of cancer cell lines (1.31 and 3.03-fold reduction in MDA-MB-231 and E0771 cells, respectively) and CSCs. In addition, MTSs treated with PTX-PLGA exhibited a more disorganized surface and significantly higher cell death rates compared to free PTX (27.9% and 16.3% less in MTSs from MCF-7 and E0771, respectively). PTX-PLGA nanoformulation preserved PTX’s mechanism of action and increased its cell internalization. Interestingly, PTX-PLGA NPs not only reduced the tumor volume of treated mice but also increased the antineoplastic drug accumulation in their lungs, liver, and spleen. In addition, mice treated with PTX-loaded NPs showed blood parameters similar to the control mice, in contrast with free PTX. Conclusion: These results suggest that our PTX-PLGA NPs could be a suitable strategy for breast cancer therapy, improving antitumor drug efficiency and reducing systemic toxicity without altering its mechanism of action.es_ES
dc.description.sponsorshipV Plan Propio (University of Seville)es_ES
dc.description.sponsorshipJunta de Andalucia PI-0102-2017 P18-HO-3882es_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.description.sponsorshipEuropean Commission PI19/01478es_ES
dc.publisherTabriz University of Medical Sciences and Health Serviceses_ES
dc.rightsAtribución-NoComercial 3.0 España*
dc.subjectBreast canceres_ES
dc.subjectCancer stem cellses_ES
dc.subjectMice xenografitses_ES
dc.titleEvaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast canceres_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial 3.0 España